Annuncio pubblicitario
Italia markets closed
  • Dow Jones

    38.506,18
    +266,20 (+0,70%)
     
  • Nasdaq

    15.681,94
    +230,64 (+1,49%)
     
  • Nikkei 225

    37.552,16
    +113,55 (+0,30%)
     
  • EUR/USD

    1,0708
    +0,0051 (+0,48%)
     
  • Bitcoin EUR

    62.314,51
    +282,97 (+0,46%)
     
  • CMC Crypto 200

    1.435,73
    +20,97 (+1,48%)
     
  • HANG SENG

    16.828,93
    +317,24 (+1,92%)
     
  • S&P 500

    5.067,80
    +57,20 (+1,14%)
     

Tecan issues CHF 250 million inaugural straight bond

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules

Männedorf, Switzerland – September 21, 2021 – Today, the Tecan Group (SIX Swiss Exchange: TECN) successfully raised CHF 250 million debt through the issuance of a fixed rate domestic straight bond. The bonds bear a 0.050% coupon and have a duration of 4 years (final maturity October 6, 2025). Settlement date of the bonds is October 6, 2021. The bonds will be listed and traded on the SIX Swiss Exchange.

The net proceeds of the issue will partly refinance the USD 1.0 billion (CHF 920 million) acquisition of Paramit Corporation, a leading OEM developer and manufacturer of medical devices and life science instruments, that was announced on June 23, 2021 and successfully closed on August 2, 2021.

ANNUNCIO PUBBLICITARIO

The bonds were placed with institutional investors and private banks in Switzerland under the joint lead management of Credit Suisse and Zürcher Kantonalbank.

About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2020, Tecan generated sales of CHF 731 million (USD 778 million; EUR 683 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For further information:

Tecan Group
Martin Braendle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

Disclaimer

This press release and the information contained herein may not be published, distributed or transmitted to the United States (USA) Canada, Australia or Japan or any other jurisdiction into which the same would be unlawful, or given or transmitted to US persons (including legal entities) or to media with a general circulation in the USA. This bond will not be publicly offered for sale outside Switzerland. This media release does not constitute an offer to buy or subscribe for securities; it is neither an issue prospectus within the meaning of Article 35 FinSA nor a listing prospectus within the meaning of the SIX Swiss Exchange Listing Rules.

Attachment